47 results on '"Bria, Emilio"'
Search Results
2. PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer
3. Patients’ perception of chemotherapy side effects: Expectations, doctor–patient communication and impact on quality of life – An Italian survey
4. Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology
5. Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer
6. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
7. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D
8. Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma
9. Treatment of Unfit Patients With Advanced Non–Small-Cell Lung Cancer: Definition Criteria According an Expert Panel
10. Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel
11. Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma
12. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents
13. ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung
14. Lung Adenocarcinoma Patient Refractory to Gefitinib and Responsive to Crizotinib, with Concurrent Rare Mutation of the Epidermal Growth Factor Receptor (L861Q) and Increased ALK/MET/ROS1 Gene Copy Number
15. Adjuvant Treatment for Resected Renal Cell Carcinoma: Are All Strategies Equally Negative? Potential Implications for Trial Design With Targeted Agents
16. Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors
17. Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR
18. EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy
19. Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies
20. Early recurrence risk: aromatase inhibitors versus tamoxifen
21. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: Meta-Analysis of Randomized Trials
22. Cetuximab for Metastatic Colorectal Cancer
23. Taxanes As Primary Chemotherapy for Early Breast Cancer: Meta-Analysis of Randomized Trials
24. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials
25. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials
26. Do Adjuvant Aromatase Inhibitors Increase the Cardiovascular Risk in Postmenopausal Women With Early Breast Cancer: Meta-Analysis of Randomized Trials
27. Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?: A meta-analysis of 20 phase 3 trials
28. Adjuvant Chemotherapy for Non-small Cell Lung Cancer
29. Peripheral Neurotoxicity of Weekly Paclitaxel Chemotherapy: A Schedule or a Dose Issue?
30. Re: Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis
31. DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer
32. Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?*
33. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients
34. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: A pooled analysis from phase III studies
35. Treatment of Resected Non-Small-Cell Lung Cancer
36. Low-Molecular-Weight Heparin Versus Oral Anticoagulant Therapy for the Long-Term Treatment of Symptomatic Venous Thromboembolism: Is There Any Difference in Cancer-Related Mortality?
37. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: A pooled analysis of the randomized trials
38. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree
39. Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer
40. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma: Pooled analysis of 2805 patients
41. Chemoradiotherapy for Rectal Cancer
42. TAXANES (PACLITAXEL AND DOCETAXEL) COMBINED WITH ANTRACYCLINES IN 1st LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER (MBC): COMPREHENSIVE REVIEW OF 2589 PATIENTS
43. MALE BREAST CANCER: A REPORT OF 27 CASES
44. Contrast-enhanced computed tomographic colonography in the follow-up of colorectal cancer patients: a feasibility study
45. Does paclitaxel (Ptx) dose & infusion time influences outcome in advanced non small cell lung cancer (NSCLC)? Comprehensive review of 2874 pts
46. Weekly epirubicin-paclitaxel as first line chemotherapy in advanced breast cancer patients: Evaluation of cardiologic toxicity
47. COLORECTAL CANCER (CRC) PATIENTS FOLLOW-UP WITH VIRTUAL COMPUTED TOMOGRAPHY COLONOGRAPHY (CTC): PRELIMINARY EXPERIENCE OF ONE DAY SCHEDULE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.